蓝帆医疗
(002382)
| 流通市值：66.33亿 | | | 总市值：66.98亿 |
| 流通股本：9.97亿 | | | 总股本：10.07亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,624,785,065.65 | 5,739,692,552.6 | 4,181,728,803.56 | 2,780,551,449.68 |
| 营业收入 | 1,624,785,065.65 | 5,739,692,552.6 | 4,181,728,803.56 | 2,780,551,449.68 |
| 二、营业总成本 | 1,574,843,236.35 | 6,183,340,015.79 | 4,540,279,927.07 | 2,960,366,551.91 |
| 营业成本 | 1,218,310,039.38 | 4,840,417,326.36 | 3,610,323,665.65 | 2,381,801,341.21 |
| 税金及附加 | 13,155,832.15 | 52,260,542.11 | 39,027,857.89 | 23,710,145.16 |
| 销售费用 | 109,663,995.47 | 485,286,788.69 | 332,425,100 | 214,511,264.44 |
| 管理费用 | 78,074,969.68 | 329,495,541.6 | 226,080,232.83 | 148,604,568.21 |
| 研发费用 | 59,496,162.87 | 254,424,847.85 | 192,637,377.01 | 122,304,096.36 |
| 财务费用 | 96,142,236.8 | 221,454,969.18 | 139,785,693.69 | 69,435,136.53 |
| 其中:利息费用 | 69,481,704.35 | 272,065,572.26 | 205,741,051.68 | 137,452,699.13 |
| 其中:利息收入 | 7,658,254.93 | 24,720,606.73 | 20,255,835.07 | 14,202,391.71 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -50,272.53 | 497,722.83 | 6,606,212.02 | 6,523,442.42 |
| 加:投资收益 | -884,733.12 | 16,798,003.93 | 13,481,981.59 | 5,592,656.84 |
| 资产处置收益 | 119,941.05 | -1,649,674.87 | -411,420.42 | -372,425.04 |
| 资产减值损失(新) | 11,776,775.09 | -177,201,253.98 | -45,173,647.69 | -68,260,025.29 |
| 信用减值损失(新) | -7,430,752.64 | -21,050,566.63 | -8,068,920.4 | 2,674,632.21 |
| 其他收益 | 6,388,880.67 | 53,269,524.89 | 46,209,170.12 | 41,978,303.89 |
| 四、营业利润 | 59,861,667.82 | -572,983,707.02 | -345,907,748.29 | -191,678,517.2 |
| 加:营业外收入 | 7,160,382.45 | 20,162,897.9 | 2,442,771.57 | 2,266,552.94 |
| 减:营业外支出 | 936,277.95 | 108,314,730.91 | 4,225,285.77 | 2,690,037.16 |
| 五、利润总额 | 66,085,772.32 | -661,135,540.03 | -347,690,262.49 | -192,102,001.42 |
| 减:所得税费用 | 32,092,785.95 | 137,275,778.27 | -44,994,047.5 | -49,283,013.74 |
| 六、净利润 | 33,992,986.37 | -798,411,318.3 | -302,696,214.99 | -142,818,987.68 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 33,992,986.37 | -798,411,318.3 | -302,696,214.99 | -142,818,987.68 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 962,845.08 | -758,940,830.72 | -285,962,030.51 | -134,779,268.14 |
| 少数股东损益 | 33,030,141.29 | -39,470,487.58 | -16,734,184.48 | -8,039,719.54 |
| 扣除非经常损益后的净利润 | -9,496,791.42 | -833,961,001.83 | -364,366,368.11 | -209,757,631.99 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0 | -0.76 | -0.28 | -0.13 |
| (二)稀释每股收益 | 0 | -0.76 | -0.28 | -0.13 |
| 八、其他综合收益 | -91,161,983.42 | -69,235,627.82 | -12,376,023.67 | 26,574,975.36 |
| 归属于母公司股东的其他综合收益 | -76,247,253.93 | -59,926,504.86 | -8,952,690.58 | 23,247,327.47 |
| 九、综合收益总额 | -57,168,997.05 | -867,646,946.12 | -315,072,238.66 | -116,244,012.32 |
| 归属于母公司股东的综合收益总额 | -75,284,408.85 | -818,867,335.58 | -294,914,721.09 | -111,531,940.67 |
| 归属于少数股东的综合收益总额 | 18,115,411.8 | -48,779,610.54 | -20,157,517.57 | -4,712,071.65 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |